{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:29:20Z","timestamp":1788262160331,"version":"build-2803163510"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T00:00:00Z","timestamp":1505088000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81370637"],"award-info":[{"award-number":["No. 81370637"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s00432-017-2517-0","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T14:02:00Z","timestamp":1505138520000},"page":"2619-2630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Higher out-of-pocket expenses for tyrosine kinase-inhibitor therapy is associated with worse health-related quality-of-life in persons with chronic myeloid leukemia"],"prefix":"10.1007","volume":"143","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7131-0522","authenticated-orcid":false,"given":"Qian","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,11]]},"reference":[{"key":"2517_CR1","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3109\/10428194.2011.560310","volume":"52","author":"Z Aziz","year":"2011","unstructured":"Aziz Z, Iqbal J, Aaqib M et al (2011) Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma 52:1017\u20131023","journal-title":"Leuk Lymphoma"},{"key":"2517_CR2","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW et al (2016) Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 34:2851\u20132857","journal-title":"J Clin Oncol"},{"key":"2517_CR3","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1007\/s00520-016-3286-z","volume":"24","author":"M Breccia","year":"2016","unstructured":"Breccia M, Graffigna G, Galimberti S et al (2016) Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis. Support Care Cancer 24:4487\u20134493","journal-title":"Support Care Cancer"},{"key":"2517_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jnci\/87.6.399","volume":"87","author":"ML Brown","year":"1995","unstructured":"Brown ML, Fireman B (1995) Evaluation of direct medical costs related to cancer. J Natl Cancer Inst 87:399\u2013400","journal-title":"J Natl Cancer Inst"},{"key":"2517_CR5","volume-title":"Cancer epidemiology and prevention","author":"ML Brown","year":"2006","unstructured":"Brown ML, Yarbroff KR (2006) Economic impact of cancer in the US. In: Schottenfield D, Fraumeni JF (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, New York","edition":"3"},{"key":"2517_CR6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.clml.2016.02.002","volume":"16","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Lipton JH, Miller CB et al (2016) Evaluating the impact of a switch to nilotinib on imatinib-related chronic low-grade adverse events in patients with CML-CP: the ENRICH study. Clin Lymphoma Myeloma Leuk 16:286\u2013296","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2517_CR7","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1200\/JCO.2013.52.9123","volume":"32","author":"SB Dusetzina","year":"2014","unstructured":"Dusetzina SB, Winn AN, Abel GA et al (2014) Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306\u2013311","journal-title":"J Clin Oncol"},{"key":"2517_CR8","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1182\/blood-2011-04-347575","volume":"118","author":"F Efficace","year":"2011","unstructured":"Efficace F, Baccarani M, Breccia M et al (2011) GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118:4554\u20134560","journal-title":"Blood"},{"key":"2517_CR9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00277-012-1458-6","volume":"91","author":"F Efficace","year":"2012","unstructured":"Efficace F, Breccia M, Saussele S et al (2012) Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group. Ann Hematol 91:1371\u20131381","journal-title":"Ann Hematol"},{"key":"2517_CR10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/leu.2013.51","volume":"27","author":"F Efficace","year":"2013","unstructured":"Efficace F, Baccarani M, Breccia M et al (2013) Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia 27:1511\u20131519","journal-title":"Leukemia"},{"key":"2517_CR11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11136-013-0523-5","volume":"23","author":"F Efficace","year":"2014","unstructured":"Efficace F, Baccarani M, Breccia M et al (2014) International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24. Qual Life Res 23:825\u2013836","journal-title":"Qual Life Res"},{"key":"2517_CR12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00277-015-2541-6","volume":"95","author":"F Efficace","year":"2016","unstructured":"Efficace F, Rosti G, Breccia M et al (2016a) The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Ann Hematol 95:211\u2013219","journal-title":"Ann Hematol"},{"key":"2517_CR13","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.1007\/s00520-016-3344-6","volume":"24","author":"F Efficace","year":"2016","unstructured":"Efficace F, Breccia M, Cottone F et al (2016b) Psychological well-being and social support in chronic myeloid leukemia patients receiving lifelong targeted therapies. Support Care Cancer 24:4887\u20134894","journal-title":"Support Care Cancer"},{"key":"2517_CR14","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","volume":"103","author":"C Gambacorti-Passerini","year":"2011","unstructured":"Gambacorti-Passerini C, Antolini L, Mahon FX et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553\u2013561","journal-title":"J Natl Cancer Inst"},{"key":"2517_CR15","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","volume":"30","author":"A Gu\u00e9rin","year":"2014","unstructured":"Gu\u00e9rin A, Chen L, Ionescu-Ittu R et al (2014) Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Curr Med Res Opin 30:2317\u20132328","journal-title":"Curr Med Res Opin"},{"key":"2517_CR16","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.3109\/10428194.2013.854886","volume":"55","author":"JF Guest","year":"2014","unstructured":"Guest JF, Gray EJ, Szczudlo T et al (2014) Utility values for specific chronic myeloid leukemia chronic phase health states from the general public in the UK. Leuk Lymphoma 55:1870\u20131875","journal-title":"Leuk Lymphoma"},{"key":"2517_CR17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/ejh.12743","volume":"97","author":"N Gunnarsson","year":"2016","unstructured":"Gunnarsson N, Sandin F, H\u00f6glund M et al (2016) Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence. Eur J Haematol 97:387\u2013392","journal-title":"Eur J Haematol"},{"key":"2517_CR18","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","volume":"21","author":"EA Hahn","year":"2003","unstructured":"Hahn EA, Glendenning GA, Sorensen MV, IRIS Investigators et al (2003) Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 21:2138\u20132146","journal-title":"J Clin Oncol"},{"key":"2517_CR19","first-page":"2113","volume":"22","author":"N Hamerschlak","year":"2014","unstructured":"Hamerschlak N, de Souza C, Cornacchioni AL et al (2014) Quality of life of chronic myeloid leukemia patients in Brazil: ability to work as a key factor. Support Care Cancer 22:2113\u20132118","journal-title":"Support Care Cancer"},{"key":"2517_CR20","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","volume":"118","author":"X Huang","year":"2012","unstructured":"Huang X, Cortes J, Kantarjian H (2012) Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer 118:3123\u20133127","journal-title":"Cancer"},{"key":"2517_CR21","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/2279-042X.128145","volume":"2","author":"P Jain","year":"2013","unstructured":"Jain P, Das VN, Ranjan A et al (2013) Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea. J Res Pharm Pract 2:156\u2013161","journal-title":"J Res Pharm Pract"},{"key":"2517_CR22","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00432-016-2158-8","volume":"142","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, Gale RP (2016) Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. J Cancer Res Clin Oncol 142:1549\u20131555","journal-title":"J Cancer Res Clin Oncol"},{"key":"2517_CR23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00432-016-2159-7","volume":"142","author":"Q Jiang","year":"2016","unstructured":"Jiang Q, Liu ZC, Zhang SX et al (2016) Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol 142:1539\u20131547","journal-title":"J Cancer Res Clin Oncol"},{"key":"2517_CR24","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2147\/PPA.S92125","volume":"9","author":"M Kek\u00e4le","year":"2015","unstructured":"Kek\u00e4le M, Peltoniemi M, Airaksinen M (2015) Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 9:1733\u20131740","journal-title":"Patient Prefer Adherence"},{"key":"2517_CR25","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.2015.63.2232","volume":"34","author":"CS Lathan","year":"2016","unstructured":"Lathan CS, Cronin A, Tucker-Seeley R et al (2016) Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol 34:1732\u20131740","journal-title":"J Clin Oncol"},{"key":"2517_CR26","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00432-016-2155-y","volume":"142","author":"M Lauseker","year":"2016","unstructured":"Lauseker M, Gerlach R, Tauscher M et al (2016) Improved survival boosts the prevalence of chronic myeloid leukemia: predictions from a population-based study. J Cancer Res Clin Oncol 142:1441\u20131447","journal-title":"J Cancer Res Clin Oncol"},{"key":"2517_CR27","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/jech.57.4.259","volume":"57","author":"L Li","year":"2003","unstructured":"Li L, Wang HM, Shen Y (2003) Chinese SF-36 Health Survey: translation, cultural adaptation, validation, and normalisation. J Epidemiol Community Health 57:259\u2013263","journal-title":"J Epidemiol Community Health"},{"key":"2517_CR28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1185\/03007995.2015.1120189","volume":"32","author":"LJ McGarry","year":"2016","unstructured":"McGarry LJ, Chen YJ, Divino V et al (2016) Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. Curr Med Res Opin 32:289\u2013299","journal-title":"Curr Med Res Opin"},{"key":"2517_CR29","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ygyno.2011.11.038","volume":"124","author":"K Meneses","year":"2012","unstructured":"Meneses K, Azuero A, Hassey L et al (2012) Does economic burden influence quality of life in breast cancer survivors? Gynecol Oncol 124:437\u2013443","journal-title":"Gynecol Oncol"},{"key":"2517_CR30","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/bmt.2013.232","volume":"49","author":"XD Mo","year":"2014","unstructured":"Mo XD, Jiang Q, Xu LP et al (2014) Health-related quality of life of patients with newly diagnosed chronic myeloid leukemia treated with allogeneic hematopoietic SCT versus imatinib. Bone Marrow Transplant 49:576\u2013580","journal-title":"Bone Marrow Transplant"},{"key":"2517_CR31","first-page":"283","volume":"75","author":"MJ Naughton","year":"2014","unstructured":"Naughton MJ, Weaver KE (2014) Physical and mental health among cancer survivors: considerations for long-term care and quality of life. N C Med J 75:283\u2013286","journal-title":"N C Med J"},{"key":"2517_CR32","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/10428194.2015.1049166","volume":"57","author":"JS Park","year":"2016","unstructured":"Park JS, Lee SE, Jeong SH et al (2016) Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients. Leuk Lymphoma 57:341\u2013347","journal-title":"Leuk Lymphoma"},{"key":"2517_CR33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00520-012-1630-5","volume":"21","author":"KM Phillips","year":"2013","unstructured":"Phillips KM, Pinilla-Ibarz J, Sotomayor E et al (2013) Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer 21:1097\u20131103","journal-title":"Support Care Cancer"},{"key":"2517_CR34","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"K Sasaki","year":"2015","unstructured":"Sasaki K, Strom SS, O\u2019Brien S et al (2015) Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials. Lancet Haematol 2:e186\u2013e193","journal-title":"Lancet Haematol"},{"key":"2517_CR35","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.2011.37.9511","volume":"30","author":"V Shankaran","year":"2012","unstructured":"Shankaran V, Jolly S, Blough D et al (2012) Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol 30:1608\u20131614","journal-title":"J Clin Oncol"},{"key":"2517_CR36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.leukres.2011.10.011","volume":"36","author":"PC Trask","year":"2012","unstructured":"Trask PC, Cella D, Besson N et al (2012) Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 36:438\u2013442","journal-title":"Leuk Res"},{"key":"2517_CR37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.leukres.2012.09.013","volume":"37","author":"PC Trask","year":"2013","unstructured":"Trask PC, CellaD Powell C et al (2013) Health-related quality of life in chronic myeloid leukemia. Leuk Res 37:9\u201313","journal-title":"Leuk Res"},{"key":"2517_CR38","first-page":"AS264","volume":"33","author":"JE Ware","year":"1995","unstructured":"Ware JE, Kosinski M, Bayliss MS et al (1995) Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. Med Care 33:AS264\u2013AS279","journal-title":"Med Care"},{"key":"2517_CR39","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/cncr.29866","volume":"122","author":"EL Warner","year":"2016","unstructured":"Warner EL, Kent EE, Trevino KM et al (2016) Social well-being among adolescents and young adults with cancer: a systematic review. Cancer 122:1029\u20131037","journal-title":"Cancer"},{"key":"2517_CR40","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1185\/03007995.2016.1174108","volume":"32","author":"J Whiteley","year":"2016","unstructured":"Whiteley J, Reisman A, Shapiro M et al (2016) Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure. Curr Med Res Opin 32:1325\u20131334","journal-title":"Curr Med Res Opin"},{"key":"2517_CR41","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ncponc0978","volume":"4","author":"KR Yabroff","year":"2007","unstructured":"Yabroff KR, Warren JL, Brown ML (2007) Costs of cancer care in the USA: a descriptive review. Nat Clin Pract Oncol 4:643\u2013656","journal-title":"Nat Clin Pract Oncol"},{"key":"2517_CR42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1634\/theoncologist.2012-0279","volume":"18","author":"SY Zafar","year":"2013","unstructured":"Zafar SY, Peppercorn JM, Schrag D et al (2013) The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient\u2019s experience. Oncologist 18:381\u2013390","journal-title":"Oncologist"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-017-2517-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-017-2517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,17]],"date-time":"2017-11-17T07:31:35Z","timestamp":1510903895000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-017-2517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,11]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2517"],"URL":"https:\/\/doi.org\/10.1007\/s00432-017-2517-0","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,11]]}}}